Axena Health Begins First-of-Its-Kind Global Study of Female Incontinence

Axena Health, Inc. (Axena Health), a women’s health medical device company focused on scalable treatments for female pelvic health, announced today a large-scale study that will investigate the burdens of incontinence on women in low- and middle-income countries to support equitable access to treatment. The first-of-its-kind study will examine how women could access treatment within local healthcare delivery systems and in a manner that accommodates cultural norms. Study results will be available in late 2023 and will inform the development of new treatment options based on the Leva^® Pelvic Health System, a digital health treatment for urinary incontinence (UI) with published studies supporting its effectiveness, including durable, long-term symptom relief. Read more.

Source: Yahoo! Finance, May 19, 2023

TENA Launches Lights Sensitive Ultra Pads Tackling a Lesser-Known Menopause Symptom

TENA, the UKs leading incontinence brand for over 60 years, has launched a new range of Lights Sensitive Ultra Pads, designed to manage bladder leaks and support healthy intimate skin. This latest product innovation features a unique skin caring emulsion that has been specifically designed for sensitive skin by helping to limit friction, making it the first of its kind to the UK market. Continuing in its mission to better support women during the menopause, the introduction of the TENA Lights Sensitive Ultra will help the large number of women who suffer with skin irritation and incontinence – two of the many lesser-known menopausal symptoms. Read more.

Source: Retail Times, November 19, 2022

BioDerm, Inc. Begins Distribution in Home Care Markets of a New Revolutionary Female Incontinence Device From TillaCare, Ltd

BioDerm is excited to partner with TillaCare as a U.S. distributor of TillaCare’s UriCap Female. UriCap Female is a revolutionary external urine collection system offering female patients with urinary incontinence a comfortable, easy-to-use solution without the skin irritation and discomfort associated with absorbent products. Following the successful launch of UriCap Female in hospital and institutional settings, BioDerm launched a direct-to-consumer campaign allowing patients to receive UriCap Female for in-home use. Read more.

Source: Index-Journal, October 28, 2022

Viveca Biomed Launches Contrelle To Create ‘Revolution’ In Tackling Stress Urinary Incontinence

Viveca Biomed has launched an innovative and clinically-proven bladder support device, Contrelle that offers women immediate relief from stress urinary incontinence (SUI) and provides community pharmacy contractors with a way to build a new consumer base, customer loyalty and sales margins. The product, named ‘Contrelle Activgard’, has already recorded millions of sales in Scandinavia over a decade. Read more.

Source: Pharmacy Business, August 24, 2022

Prasterone Shows Promise In Reducing Severity of Urinary Urge Incontinence

Because of a decrease in estrogen, menopause is often accompanied by multiple vaginal and urinary issues. To date, most treatment options focus on vulvar and vaginal atrophy, with fewer options available to treat urinary incontinence. A new study, however, suggests prasterone is effective in improving the severity of urinary urge incontinence. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS). Read more.

Source: Newswise, July 27, 2022

First Quality Introduces MaxSorb+ Zone For Bladder Control Pads

First Quality Products, Inc. is launching a new technology for bladder control pads called MaxSorb+ Zone, providing enhanced rapid absorption to help keep skin dry all day and support skin health. Pads that use First Quality’s MaxSorb+ Zone absorb up to 50% faster compared to previous Prevail bladder control pads. Read more.

Source: Nonwovens Industry, April 28, 2022

pelvic vaginal mesh stress urinary incontinence Polypropylene vaginal mesh

Newer Mesh Slings for Stress Incontinence a Safe, Effective Option for Women: Study

For women with frequent urine leakage, a newer and simpler “sling” surgery works as well as the standard version, according to a new clinical trial. The study involved women with stress urinary incontinence, where movement that puts pressure on the abdomen — such as running, lifting, coughing or laughing — causes urine leakage. When the condition is severe, surgery may be recommended. Read more.

Source: HealthDay News, March 31, 2022

First Patients Enrolled in Uromedica’s Adjustable Continence Therapy (ACT®) for Female Stress Urinary Incontinence (SUI) Trial

Uromedica, Inc. announces the initiation of its FDA Investigational Device Exemption trial for ACT® to evaluate its safety and efficacy for treatment of female SUI. Stress urinary incontinence is the accidental leakage of urine that can occur when sneezing, coughing, or performing physical activity. The investigational intent of the ACT trial, a post-operatively adjustable, minimally invasive outpatient procedure, is to assess safety and efficacy for women who suffer from moderate or severe SUI. Read more.

Source: Business Wire, March 10, 2021

Elidah Announces the Launch of ELITONE® – A New Non-Invasive Treatment for Women’s Incontinence

Elidah, Inc (https://elitone.com/), a woman-owned medical device company, today announced the launch of ELITONE®, the first and only patented medical device providing non-invasive treatment for stress urinary incontinence in women. ELITONE is the first product of its kind launched under a newly created FDA product category for non-invasive incontinence therapy. Stress urinary incontinence is the loss of bladder control when activities such as exercising, coughing, laughing or sneezing increase the internal pressure placed on the abdominal cavity and pelvic floor muscles. Read more.

Source: PRNewswire, August 20, 2019

FemTech – Making strides for women

While EU Member States discuss the Health Technology Assessment proposal, an EU-wide research tool to support decision-making on health technologies and innovation in the “FemTech” sector (encompassing fertility, pregnancy and nursing care, women’s sexual wellness and e-health technologies) promises to revolutionise the treatment of pelvic floor dysfunctions for women across Europe and beyond. Over 50 percent of women worldwide suffer from at least one of the following three pelvic floor dysfunctions: Stress urinary incontinence, faecal incontinence, and pelvic organ prolapse (POP). Read more.

Source: The Parliament, July 23, 2019